# AsclepiX Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/asclepix-therapeutics

- Industry: Biotechnology
- Headquarters: Baltimore, US
- Website: www.asclepix.com
- Total disclosed funding: $20M
- Latest round: Series A (Jul 26, 2023)
- Investors on record: 4

## About

AsclepiX Therapeutics, Inc. focuses on pioneering therapies for ocular diseases, particularly with its lead product AXT107, designed to inhibit critical factors involved in retinal vascular diseases.Founded in 2011 in Baltimore, US, AsclepiX Therapeutics, Inc. specializes in innovative treatments for ocular diseases. The company has successfully completed 3 deals, including its latest Series A funding round in July 2023, raising USD 10.000 mn led by Perceptive Advisors. Co-founded by Aleksander Popel and Jordan Green, the company aims to enhance treatment options for retinal diseases.AsclepiX Therapeutics specializes in the development of innovative therapies for ocular diseases, focusing on their lead product, AXT107. This therapeutic candidate inhibits the pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2) and activates the vessel stabilizing receptor tyrosine kinase (Tie2), addressing critical pathways in retinal vascular disease treatment. AXT107 is administered through intraocular injection and targets conditions such as wet age-related macular degeneration (AMD), primarily in North America and Europe.AsclepiX Therapeutics generates revenue through the clinical development and potential commercialization of its therapeutic candidates, with a focus on AXT107. Revenue is tied to successful trial outcomes, partnerships with healthcare providers, and distribution agreements, with the company advancing AXT107 through the DISCOVER study evaluating its efficacy in treating wet AMD.In July 2023, AsclepiX Therapeutics raised USD 10.000 mn in Series A-3 funding to support the clinical study of AXT107 in patients with wet age-related macular degeneration (wet AMD). The funds will facilitate the evaluation of AXT107's effectiveness against wet AMD, further solidifying the company's commitment to addressing unmet medical needs in this area.

## Funding rounds

- Series A, Jul 26, 2023, $10M — Perceptive Advisors, Rapha Capital Management, Hibiscus BioVentures
- Series A, May 27, 2020, $10M — Perceptive Advisors, Barer & Son Capital, Rapha Capital Management

## Investors

- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A
- Barer & Son Capital — Series A
- Rapha Capital Management (https://capitalatlas.ai/funds/rapha-capital-management) — Series A
- Hibiscus BioVentures (https://capitalatlas.ai/funds/hibiscus-bioventures) — Series A